Critical Illness Cover for Cancer UK: How Claims Work

Why cancer dominates critical illness claims

Cancer is consistently the most common reason critical illness claims are made and paid, according to the protection claims data the ABI publishes for its member insurers. This reflects the prevalence of cancer in the UK population and the fact that many cancers, when caught and treated, lead to a period of reduced earnings, time off work and additional costs that the lump sum is designed to cushion.

Because cancer drives so many claims, it is also the condition where the precise policy definition matters most. A diagnosis of "cancer" in everyday language does not automatically trigger a payout. The policy pays only if the diagnosis meets the contractual definition, which is built around the medical concept of an invasive malignant tumour rather than any abnormal cell growth. Understanding that distinction is the key to knowing whether a particular diagnosis would qualify.

The benefit, when paid, is a tax-free lump sum to the living policyholder, and is regulated by the FCA as part of a pure protection contract under ICOBS.

How the policy defines covered cancer

The ABI's Statement of Best Practice sets out a model definition of cancer that most insurers adopt as a baseline. In broad terms, the covered definition requires a malignant tumour characterised by uncontrolled growth and the invasion of surrounding tissue, confirmed by appropriate medical evidence. This standardisation means the core meaning of "cancer" is broadly consistent across the market, even though insurers may add wording around specific cancer types.

The definition deliberately distinguishes between cancers that are invasive and those that are not. Invasive malignant cancers that have spread beyond their original layer of tissue generally qualify for the full benefit. Non-invasive conditions, where abnormal cells are confined to where they started (described medically as "in situ"), often fall outside the full definition because they have not yet invaded surrounding tissue.

Insurers also commonly list specific cancer-related exclusions in the wording. These vary, which is why two policies covering "cancer" can produce different outcomes for the same diagnosis. Reading the cancer definition and its carve-outs in full is the only reliable way to know how a particular policy responds.

Early-stage and in-situ cancers: partial payments

The most important nuance for cancer claims is how policies treat early-stage and in-situ cancers. Rather than declining these outright, many modern policies pay a smaller, capped partial benefit for specified less advanced cancers. Common examples treated this way include carcinoma in situ of the breast, certain low-grade or early prostate cancers, and some non-invasive conditions. The partial payment is typically a fraction of the full sum assured up to a stated cap.

A crucial feature of most partial payments is that they do not reduce the remaining sum assured. The policyholder receives the partial amount, the main cover continues unchanged, and a later, more serious qualifying diagnosis could still trigger the full benefit. This is a meaningful advance on older policies that either paid nothing for early-stage cancers or exhausted the whole sum assured on a partial event.

The exact list of conditions that attract a partial payment, and the cap that applies, differ between insurers. Some policies also include additional or "enhanced" cancer cover options. Checking how a policy handles in-situ and early-stage cancer is therefore one of the most practical comparisons a buyer can make.

How a cancer claim is assessed

When a cancer claim is submitted, the insurer obtains medical evidence, usually from the treating oncologist, histopathology reports and the GP, to confirm the type, grade and stage of the cancer. The assessment compares that clinical evidence against the policy's cancer definition and any partial-payment categories. The decision turns on objective medical facts: whether the tumour is malignant, whether it is invasive, and how it is classified, rather than on a subjective view of how unwell the person feels.

Most policies require the policyholder to survive a short period after diagnosis, commonly 10 to 14 days, before the claim is payable. Provided the diagnosis meets the definition and the survival period is satisfied, the lump sum is paid. Where the diagnosis matches a partial-payment category, the smaller benefit is paid and the main cover continues.

Disclosure remains central to a successful claim. Under the Consumer Insurance (Disclosure and Representations) Act 2012, the applicant must take reasonable care not to make a misrepresentation when answering the insurer's health and family-history questions. Symptoms investigated before the policy started, or a relevant family history, must be disclosed accurately, because careless or deliberate inaccuracy can let the insurer reduce or refuse a cancer claim later.

If a cancer claim is declined

Declined cancer claims most often arise where the diagnosis does not meet the invasive-malignant definition (for example a purely in-situ condition that the policy excludes from the full benefit), where a survival period is not met, or where there has been non-disclosure of earlier symptoms or investigations. In some of these cases a partial payment may still apply even though the full benefit does not.

If a policyholder believes a cancer claim has been wrongly declined, the first step is the insurer's own complaints process. If that does not resolve matters, the complaint can be referred free of charge to the Financial Ombudsman Service, which can examine whether the cancer definition was applied fairly, whether any non-disclosure was genuinely careless or deliberate, and whether the insurer treated the customer fairly overall. The Ombudsman's decision is binding on the firm if the consumer accepts it.

Because outcomes hinge so heavily on definitions and disclosure, keeping copies of the original application answers and obtaining the full medical reports can be valuable if a dispute arises.

Frequently asked questions

Does critical illness cover pay out for all types of cancer?

No. Policies generally pay the full benefit for invasive malignant cancers that meet the definition. Many early-stage, in-situ or low-grade cancers are excluded from the full payout, though they may attract a smaller partial benefit depending on the policy.

What is an in-situ cancer and is it covered?

An in-situ cancer is one where abnormal cells remain confined to where they started and have not invaded surrounding tissue. These are often outside the full cancer definition but are commonly paid as a capped partial benefit that leaves the main cover intact.

Does a partial cancer payment reduce my cover?

In most modern policies a partial payment does not reduce the remaining sum assured. The policyholder receives the smaller amount and the main cover continues, so a later qualifying diagnosis could still trigger the full benefit.

Is cancer the most common critical illness claim?

Yes. The ABI's protection claims data shows cancer is consistently the single largest cause of critical illness claims, reflecting how common cancer is in the UK population.

Will pre-existing symptoms affect a cancer claim?

They can. Symptoms or investigations before the policy started must be disclosed honestly under the Consumer Insurance (Disclosure and Representations) Act 2012. Non-disclosure of relevant history can allow the insurer to reduce or refuse a claim.

What can I do if my cancer claim is declined?

Use the insurer's complaints process first, then refer the matter to the Financial Ombudsman Service if it is unresolved. The Ombudsman can review whether the cancer definition was applied fairly and whether any non-disclosure was careless or deliberate.